| # | Title | Journal | Year | Citations |
|---|
| 1 | Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma | Annals of Oncology | 2020 | 316 |
| 2 | Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets | Cell Metabolism | 2021 | 211 |
| 3 | Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) | European Journal of Cancer | 2020 | 122 |
| 4 | Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study | Annals of Oncology | 2015 | 113 |
| 5 | Technological advances towards extracellular vesicles mass production | Advanced Drug Delivery Reviews | 2021 | 63 |
| 6 | PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer | European Journal of Cancer | 2017 | 48 |
| 7 | Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study | ESMO Open | 2021 | 36 |
| 8 | Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial | Journal of Clinical Oncology | 2021 | 35 |
| 9 | Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer | Npj Breast Cancer | 2021 | 33 |
| 10 | Enhanced recovery after surgery program in Gynaecologic Oncological surgery in a minimally invasive techniques expert center | BMC Surgery | 2017 | 32 |
| 11 | A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer | BMC Cancer | 2010 | 28 |
| 12 | A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study | Annals of Oncology | 2016 | 25 |
| 13 | New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices? | Cancers | 2020 | 25 |
| 14 | Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial | ESMO Open | 2021 | 25 |
| 15 | Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study | European Journal of Cancer | 2017 | 24 |
| 16 | Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers | European Journal of Cancer | 2022 | 24 |
| 17 | Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit | Breast Cancer Research and Treatment | 2019 | 20 |
| 18 | Adjuvant chemotherapy for small, lymph node–negative, triple‐negative breast cancer: A single‐center study and a meta‐analysis of the published literature | Cancer | 2020 | 20 |
| 19 | RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD). | Journal of Clinical Oncology | 2019 | 20 |
| 20 | Enhancing Abiraterone Acetate Efficacy in Androgen Receptor–positive Triple-negative Breast Cancer: Chk1 as a Potential Target | Clinical Cancer Research | 2019 | 19 |
| 21 | TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT | EMBO Molecular Medicine | 2022 | 17 |
| 22 | A comprehensive approach to the molecular determinants of lifespan using a Boolean model of geroconversion | Aging Cell | 2016 | 16 |
| 23 | Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact | Breast Cancer Research and Treatment | 2019 | 16 |
| 24 | Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI). | Journal of Clinical Oncology | 2021 | 15 |
| 25 | Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors | Oncologist | 2022 | 14 |
| 26 | Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort☆ | ESMO Open | 2021 | 13 |
| 27 | Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies | Therapeutic Advances in Medical Oncology | 2022 | 13 |
| 28 | Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey | Cancers | 2020 | 12 |
| 29 | Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients | Annals of Oncology | 2022 | 12 |
| 30 | Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET) | Angiogenesis | 2020 | 11 |
| 31 | PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles’ heel? | Clinics and Research in Hepatology and Gastroenterology | 2021 | 11 |
| 32 | Enhanced recovery after surgery program in older patients undergoing gynaecologic oncological surgery is feasible and safe | Gynecologic Oncology | 2018 | 10 |
| 33 | The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients | EBioMedicine | 2020 | 10 |
| 34 | Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer | International Journal of Cancer | 2021 | 8 |
| 35 | Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin | Cancers | 2019 | 7 |
| 36 | A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers | Cancers | 2019 | 6 |
| 37 | Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma | Cancers | 2022 | 6 |
| 38 | Distinct Experimental Efficacy of Anti-Fas/APO-1/CD95 Receptor Antibody in Human Tumors | Experimental Cell Research | 2001 | 5 |
| 39 | Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases. | Journal of Clinical Oncology | 2021 | 5 |
| 40 | TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in HER2-negative locally advanced (LA) or metastatic breast cancer (MBC) patients. | Journal of Clinical Oncology | 2019 | 5 |
| 41 | FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study | International Journal of Cancer | 2022 | 5 |
| 42 | The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro‐metastases | Cancer Medicine | 2023 | 5 |
| 43 | Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG)— COMET study. | Journal of Clinical Oncology | 2019 | 4 |
| 44 | Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group | ESMO Open | 2023 | 4 |
| 45 | Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program | Oncogene | 2023 | 4 |
| 46 | Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction | Cells | 2023 | 4 |
| 47 | Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database | Gynecologic Oncology | 2021 | 3 |
| 48 | First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study | Digestive and Liver Disease | 2021 | 3 |
| 49 | CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response | Cancers | 2022 | 3 |
| 50 | 177P Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT) | Annals of Oncology | 2022 | 2 |
